Enhancing SUV Accuracy of PET/MR for Clinical Trial Qualification
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/21/2019 |
| Start Date: | January 28, 2019 |
| End Date: | June 2021 |
| Contact: | Raymond F. Muzic, PhD |
| Email: | Raymond.Muzic@uhhospitals.org |
| Phone: | 216-844-3543 |
Standardized Uptake Values (SUVs), normalized activity concentration, measured using PET/MR
have inaccuracies ≥ 20% which exceeds National Cancer Institute / American College of
Radiology Imaging Network (NCI/ACRIN), Radiological Society of North America / Quantitative
Imaging Biomarkers Alliance (RSNA/QIBA) specifications and disqualifies PET/MR from
multicenter or cooperative group clinical trials. High inaccuracy is primarily due to poor
attenuation correction (AC) owing to lack of computed tomography (CT) data. This study will
develop acquisition and analyses methods to synthesize CT images from MR data that can be
used to achieve SUVs that are within 5% of those obtained using PET/CT (reference standard),
thus meeting accuracy requirements needed to qualify for multicenter trials.
The overall goal of this research project is to validate clinically practical methods for
producing MR-based attenuation correction information which is needed to produce
quantitatively accurate PET images from a PET/MR scanner. Existing commercial PET/MR systems
use methods that are inaccurate.
have inaccuracies ≥ 20% which exceeds National Cancer Institute / American College of
Radiology Imaging Network (NCI/ACRIN), Radiological Society of North America / Quantitative
Imaging Biomarkers Alliance (RSNA/QIBA) specifications and disqualifies PET/MR from
multicenter or cooperative group clinical trials. High inaccuracy is primarily due to poor
attenuation correction (AC) owing to lack of computed tomography (CT) data. This study will
develop acquisition and analyses methods to synthesize CT images from MR data that can be
used to achieve SUVs that are within 5% of those obtained using PET/CT (reference standard),
thus meeting accuracy requirements needed to qualify for multicenter trials.
The overall goal of this research project is to validate clinically practical methods for
producing MR-based attenuation correction information which is needed to produce
quantitatively accurate PET images from a PET/MR scanner. Existing commercial PET/MR systems
use methods that are inaccurate.
Objective The primary objective is to demonstrate that, using the new acquisition and
analysis methods for MR-AC, PET SUVs in lesions and normal tissues can be measured using
PET/MR and be within 5% agreement of those measured using PET/CT.
The secondary objective is to demonstrate visual and quantitative agreement between
synthesized CT images generated from MR data and the reference, measured CT images.
Study Design This study would like to enroll patients receiving a clinically indicated PET/CT
scan. The patients will be asked to agree to a receive research PET/MR scan within the study
which requires additional time and potential MR risks for the patient. It does not entail
extra injections or radiation exposure. Research acquisition and processing will be performed
on the PET/MR data to create PET images that are expected to have quantitatively accurate
SUVs. These will be compared to SUVs from the clinical PET/CT which will serve as the
reference standard.
Outcome By bringing together cutting-edge advances in both MR acquisition and image analyses,
the successful completion of these aims will achieve SUVs that are within 5% of those
obtained with PET/CT (reference standard) with clinically appropriate acquisition time, image
quality, and diagnostic accuracy, so that PET/MR systems meet SUV accuracy requirements
needed to qualify for cooperative group clinical trials.
analysis methods for MR-AC, PET SUVs in lesions and normal tissues can be measured using
PET/MR and be within 5% agreement of those measured using PET/CT.
The secondary objective is to demonstrate visual and quantitative agreement between
synthesized CT images generated from MR data and the reference, measured CT images.
Study Design This study would like to enroll patients receiving a clinically indicated PET/CT
scan. The patients will be asked to agree to a receive research PET/MR scan within the study
which requires additional time and potential MR risks for the patient. It does not entail
extra injections or radiation exposure. Research acquisition and processing will be performed
on the PET/MR data to create PET images that are expected to have quantitatively accurate
SUVs. These will be compared to SUVs from the clinical PET/CT which will serve as the
reference standard.
Outcome By bringing together cutting-edge advances in both MR acquisition and image analyses,
the successful completion of these aims will achieve SUVs that are within 5% of those
obtained with PET/CT (reference standard) with clinically appropriate acquisition time, image
quality, and diagnostic accuracy, so that PET/MR systems meet SUV accuracy requirements
needed to qualify for cooperative group clinical trials.
Inclusion Criteria:
- Receiving PET/CT at University Hospitals Cleveland Medical Center (UHCMC) for a
clinical indication
- No Contraindications to undergo MR as assessed using University Hospitals (UH)
Radiology standard MR assessment form
- Has the ability to understand and willingness to sign a written informed consent
- The circumference of the volunteer in the body section, as determined using a
measuring tape, to be scanned must be less than or equal to 110 cm to avoid field of
view limitations on the PET/MR
Exclusion Criteria:
- Patient size or circumference greater than the MR gantry of the PET/MR.
- Pregnancy or lactation.
- Contraindications to undergo MR as assessed using UH Radiology standard MR assessment
form.
- Claustrophobia or inability to tolerate MR examination (lay still for approximately 1
hour and hold breath intermittently).
- Individuals who are not willing or capable of giving informed consent or assent (with
legal guardian consent).
We found this trial at
1
site
Cleveland, Ohio 44106
Principal Investigator: Raymond F. Muzic, PhD
Phone: 800-641-2422
Click here to add this to my saved trials
